Nodular malignant lymphomas: factors affecting complete response rate and survival
- PMID: 509385
- DOI: 10.1002/1097-0142(197912)44:6<1983::aid-cncr2820440604>3.0.co;2-4
Nodular malignant lymphomas: factors affecting complete response rate and survival
Abstract
The records of 109 patients with non-Hodgkin's lymphoma of nodular pattern were reviewed to determine which factors were associated with a favorable response to therapy and prolonged survival. A logistic regression model was utilized to identify the pertinent variables. Prognostic factors associated with a favorable response were, in order of decreasing importance: treatment with an Adriamycin combination regimen, absence of bulky tumor, and no exposure to prior chemotherapy. Thos associated with prolonged survival were: normal hemoglobin level, treatment with an Adriamycin combination regimen, female sex, and no prior exposure to therapy. Achievement of complete remission in these disorders resulted in a statistically longer duration of survival compared to partial responses or failures. Patients whose complete remission was induced with an Adriamycin-containing regimen and maintained with BCG immunotherapy had a significantly longer complete remission than those who did not receive BCG. Knowledge of these factors can be important in planning and analyzing future therapeutic trials.
Similar articles
-
BCG in the immunotherapy of non-Hodgkin's malignant lymphomas: preliminary results of a controlled trial.Recent Results Cancer Res. 1978;65:160-3. doi: 10.1007/978-3-642-81249-1_19. Recent Results Cancer Res. 1978. PMID: 370938 Clinical Trial.
-
Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.Cancer. 1979 Feb;43(2):417-25. doi: 10.1002/1097-0142(197902)43:2<417::aid-cncr2820430203>3.0.co;2-i. Cancer. 1979. PMID: 84706 Clinical Trial.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.Arch Intern Med. 1978 Mar;138(3):413-8. Arch Intern Med. 1978. PMID: 629636
-
Diffuse aggressive lymphoma.Hematology Am Soc Hematol Educ Program. 2004:221-36. doi: 10.1182/asheducation-2004.1.221. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561685 Review.
Cited by
-
The significance of the number of centroblasts in centroblastic/centrocytic lymphomas. A long term study in a large group of patients.Virchows Arch A Pathol Anat Histopathol. 1985;405(3):325-31. doi: 10.1007/BF00710068. Virchows Arch A Pathol Anat Histopathol. 1985. PMID: 3919499
-
Histological, epidemiological and clinical aspects of centroblastic-centrocytic lymphomas subdivided according to the "working formulation".Br J Cancer. 1984 Mar;49(3):263-8. doi: 10.1038/bjc.1984.43. Br J Cancer. 1984. PMID: 6367799 Free PMC article.
-
Are follicular large centrocytic and large centroblastic lymphomas one entity?Br J Cancer. 1984 Nov;50(5):727-8. doi: 10.1038/bjc.1984.245. Br J Cancer. 1984. PMID: 6388615 Free PMC article. No abstract available.